Beryl Drugs Limited - Company Profile

It is a pharma public limited company based in Indore, Madhya Pradesh, India, established in 1993.
1993 Indore, Madhya Pradesh, India Active
Last Updated:
Access Report
About Beryl Drugs Limited

Beryl Drugs Limited, a active public limited company, was established on 24 August 1993 in Indore, Madhya Pradesh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L02423MP1993PLC007840. Registered under ROC Roc Gwalior. it is listed on BSE: 524606. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹5.07 Cr.

It upholds a compliant status. In 2025, it reported revenue of ₹22.55 Cr and a net worth of ₹9.50 Cr. Employing 22 professional, Its leadership includes Sudhir Sethi (Director), Abhinav Naik (Director), Shreya Saraf (Director). Past directors included Bagachand Jain, Sudhir Sethi, Abhinav Naik. It holds ₹5.75 Cr open charges and ₹7.09 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at 133 Kanchan Bagh, Indore, Madhya Pradesh, 452001.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L02423MP1993PLC007840

  • Registration Number

    007840

  • Incorporation Date

    24 August 1993

  • Authorized Capital

    ₹10.00 Cr

  • Paid-Up Capital

    ₹5.07 Cr

  • ROC Code

    Roc Gwalior

  • Listing Status

    Listed (BSE: 524606)

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 10.00 Cr
  • Paid Up Capital ₹ 5.07 Cr
  • Company Age 32 Year, 9 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 5.75 Cr
  • Satisfied Charges ₹ 7.09 Cr
  • Revenue Growth **** -16.85%
  • Profit Growth **** -25.4%
  • Ebitda **** -1.23%
  • Net Worth 6.51%
  • Total Assets -8.22%
Company report

Beryl Drugs Limited

Company Report FY 2026-2027

Comprehensive Company Insights

Explore comprehensive insights into Beryl Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Beryl Drugs Limited?
Current Directors
Name Designation Appointment Date Status
Sudhir Sethi Director 12 Dec 2000 Current
Abhinav Naik Director 30 May 2019 Current
Shreya Saraf Director 30 May 2019 Current
Sanjay Sethi Managing Director 12 Dec 2000 Current
Shailendra Pathak Additional Director 03 Jan 2026 Current
Neha Sarda Additional Director 03 Jan 2026 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 30 Dec 2015 Past
Pramod Abcsdd Whole-Time Director 04 Sep 2014 Past
Pramod Abcsdd Additional Director 30 Sep 2019 Past
Pramod Abcsdd Additional Director 30 Sep 2019 Past
Pramod Abcsdd Director 30 Dec 2015 Past
Pramod Abcsdd Director 03 Aug 2007 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Beryl Drugs.

Beryl Drugs Limited, for the financial year ended 2025, experienced significant reduction in revenue, with a 16.85% decrease. The company also saw a substantial fall in profitability, with a 25.4% decrease in profit. The company's net worth moved up by a moderate rise of 6.51%.

Beryl Drugs revenue growth over time
Beryl Drugs profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -16.85%
*******
*******
*******
*******
Revenue from Operations
*******
 -20.89%
*******
*******
*******
*******
Total Assets
*******
 -8.22%
*******
*******
*******
*******
Profit or Loss
*******
 -25.4%
*******
*******
*******
*******
Net Worth
*******
 6.51%
*******
*******
*******
*******
EBITDA
*******
 -1.23%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Beryl Drugs?

In 2023, Beryl Drugs had a promoter holding of 26.38% and a public holding of 73.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹57,500,000.00

Satisfied Charges

₹70,875,000.00

Charges Breakdown by Lending Institutions
  • Others : 5.75 Cr
Latest Charge Details
Date Lender Amount Status
27 Jun 2024 Others ₹1.75 Cr Open
20 Mar 2023 Others ₹1.15 Cr Open
18 Mar 1997 Others ₹2.85 Cr Open
16 May 2024 Others ₹4.50 M Satisfied
12 Jun 2020 Others ₹4.50 M Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Beryl Drugs?

Beryl Drugs has a workforce of 22 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Beryl Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Beryl Drugs's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Beryl Drugs
Recent Activity within the Organization
  • Director Appointment

    Progress on Kamlesh Gupta was appointed as a Company Secretary was appointed as a Company Secretary on 24 Jan 2026 & has been associated with this company since 4 months 6 days . was documented.

  • Director Appointment

    The activity Shailendra Pathak was appointed as a Additional Director was appointed as a Additional Director on 03 Jan 2026 & has been associated with this company since 4 months 27 days . was completed.

  • Director Appointment

    Neha Sarda was appointed as a Additional Director was appointed as a Additional Director on 03 Jan 2026 & has been associated with this company since 4 months 27 days . was recorded as a recent event.

  • Annual General Meeting

    Progress on Beryl Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Charges

    Progress on A charge registered on 16 May 2024 via Charge ID 100930830 with Others was fully satisfied on 15 Apr 2025. was documented.

  • Balance Sheet

    Progress on Beryl Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Beryl Drugs Limited?

The CIN of Beryl Drugs Limited is L02423MP1993PLC007840.

Where is Beryl Drugs Limited headquartered?

Beryl Drugs Limited is headquartered at 133 Kanchan Bagh, Indore, Madhya Pradesh, 452001.

When was Beryl Drugs Limited incorporated?

Beryl Drugs Limited was incorporated on 24 August 1993.

Who are the current directors of Beryl Drugs Limited?

The current directors of Beryl Drugs Limited are

What is the primary industry of Beryl Drugs Limited?

The primary industry of Beryl Drugs Limited is Manufacturing.

Is Beryl Drugs Limited a listed company?

Beryl Drugs Limited is listed. It is listed on BSE: 524606.

What is the capital structure of Beryl Drugs Limited?

The authorized capital of Beryl Drugs Limited is ₹10.00 Cr, and the paid-up capital is ₹5.07 Cr.

What is the compliance status of Beryl Drugs Limited?

The compliance status of Beryl Drugs Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available